Vitamin D could reduce cancer risk
Vitamin D: safe in doses up to 2,000IU daily |
Supplementation with 1,000IU of vitamin D3 daily could reduce the incidence of colon, breast, prostate and ovarian cancer, at low cost and with few adverse effects, according to researchers at the Moores Cancer Centre, University of California, San Diego.
They conducted a systematic review of 63 observational studies of vitamin
D status in relation to cancer risk. The review included 30 studies of
colon cancer, 13 of breast, 26 of prostate and seven of ovarian cancer.
The researchers found that most studies showed a protective relationship
between adequate vitamin D levels and risk of cancer.
The review also highlighted that African-Americans, who have higher rates
of mortality for colon, breast, prostate and ovarian cancer, have approximately
half the plasma level of vitamin D as white people because increased
skin pigmentation reduces their ability to synthesise vitamin D.
The researchers say that a dose of 1,000IU of vitamin D3 (25µg)
daily should maintain serum levels of vitamin D at or above 30ng/ml in
most people. Throughout the US, exposure to sunlight for 15 minutes per
day between 11am and 2pm, in the summer, under clear skies, should maintain
a similar level. However, the researchers warn that if sunlight is used
as a source of vitamin D, exposure should be scrupulously monitored so
that no reddening of the skin occurs. “Oral vitamin D3 supplementation,
rather than solar exposure, should be used by fair skinned or sun-sensitive
persons, or by individuals taking medicines causing photosensitivity.” They
add that according to the National Academy of Sciences, no known health
risks are associated with doses of vitamin D up to 2,000IU daily.
“
Strong evidence indicates that intake or synthesis of vitamin D is associated
with reduced incidence and death rates of colon, breast, prostate and
ovarian cancers,” they say. However, despite these reassuring studies,
the public health and medical communities have failed to adopt its use
for cancer prevention, they point out. “Leadership from the public
health community will provide the best hope for action,” they conclude
(American Journal of Public Health 2006;96:9).
Broad spectrum p10 |
The
Pharmaceutical Journal
Acrobat
Reader